Roundtable Discussion: Marijuana Rescheduling, Cannabidiol (CBD) Product Pathways, and More
While interest in cannabis and cannabis-derived products remains high, the near- and long-term future of federal regulation remains hazy. Hear directly from FDA as they discuss regulation and enforcement in light of legal and practical challenges, followed by stakeholders sharing their perspectives on marijuana rescheduling, legislation creating CBD product pathways, and other potential steps to move federal regulation forward.
Related Professional
